(21) International Application Number: PCT/US98/14944
(22) International Filing Date: 20 July 1998 (20.07.98)
(30) Priority Data: 08/906,365 5 August 1997 (05.08.97) US


(72) Inventors: BHAT, Ramesh, A.; 738 Champlain Drive, King of Prussia, PA 19406 (US). HENDERSON, Ruth, Ann; 1414 Conway Drive, Swarthmore, PA 19081 (US). HSIAO, Chulai; 1907 Harwyn Road, Wilmington, DE 19810 (US). KARATHANASIS, Sotirios, Konstantinou; 862 Old State Road, Berwyn, PA 19312-1443 (US).


(54) Title: HUMAN ESTROGEN RECEPTOR–BETA

(57) Abstract

The present invention provides isolated nucleic acids encoding full-length human estrogen receptor–β (hERβ), which comprises 530 amino acids. The invention also provides isolated hERβ polypeptides and hERβ–reactive antibodies, including those that specifically recognize amino acids 1–45 of hERβ. The invention also encompasses methods for identifying hERβ–interactive compounds, including agonists, antagonists, and co-activators.
### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AL</td>
<td>Albania</td>
<td>ES</td>
<td>Spain</td>
<td>LS</td>
<td>Lesotho</td>
</tr>
<tr>
<td>AM</td>
<td>Armenia</td>
<td>FI</td>
<td>Finland</td>
<td>LT</td>
<td>Lithuania</td>
</tr>
<tr>
<td>AT</td>
<td>Austria</td>
<td>FR</td>
<td>France</td>
<td>LU</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GA</td>
<td>Gabon</td>
<td>LV</td>
<td>Latvia</td>
</tr>
<tr>
<td>AZ</td>
<td>Azerbaijan</td>
<td>GB</td>
<td>United Kingdom</td>
<td>MC</td>
<td>Monaco</td>
</tr>
<tr>
<td>BA</td>
<td>Bosnia and Herzegovina</td>
<td>GE</td>
<td>Georgia</td>
<td>MD</td>
<td>Republic of Moldova</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GH</td>
<td>Ghana</td>
<td>MG</td>
<td>Madagascar</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GN</td>
<td>Guinea</td>
<td>MK</td>
<td>The former Yugoslavia</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>GR</td>
<td>Greece</td>
<td>ML</td>
<td>Mali</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>HU</td>
<td>Hungary</td>
<td>MN</td>
<td>Mongolia</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>IE</td>
<td>Ireland</td>
<td>MR</td>
<td>Mauritania</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>IL</td>
<td>Israel</td>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
<td>IS</td>
<td>Iceland</td>
<td>MX</td>
<td>Mexico</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>IT</td>
<td>Italy</td>
<td>NE</td>
<td>Niger</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>JP</td>
<td>Japan</td>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KE</td>
<td>Kenya</td>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KG</td>
<td>Kyrgyzstan</td>
<td>NZ</td>
<td>New Zealand</td>
</tr>
<tr>
<td>CI</td>
<td>Côte d'Ivoire</td>
<td>KP</td>
<td>Democratic People's Republic of Korea</td>
<td>PL</td>
<td>Poland</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>KR</td>
<td>Republic of Korea</td>
<td>PT</td>
<td>Portugal</td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
<td>KZ</td>
<td>Kazakhstan</td>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>CU</td>
<td>Cuba</td>
<td>LC</td>
<td>Saint Lucia</td>
<td>RU</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>LI</td>
<td>Liechtenstein</td>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>LK</td>
<td>Sri Lanka</td>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>LR</td>
<td>Liberia</td>
<td>SG</td>
<td>Singapore</td>
</tr>
<tr>
<td>EE</td>
<td>Estonia</td>
<td></td>
<td></td>
<td>SI</td>
<td>Slovenia</td>
</tr>
<tr>
<td>SK</td>
<td>Slovakia</td>
<td>SN</td>
<td>Senegal</td>
<td>SZ</td>
<td>Swaziland</td>
</tr>
<tr>
<td>TD</td>
<td>Chad</td>
<td>TG</td>
<td>Togo</td>
<td>TJ</td>
<td>Tajikistan</td>
</tr>
<tr>
<td>TM</td>
<td>Turkmenistan</td>
<td>TR</td>
<td>Turkey</td>
<td>TT</td>
<td>Trinidad and Tobago</td>
</tr>
<tr>
<td>UA</td>
<td>Ukraine</td>
<td>UG</td>
<td>Uganda</td>
<td>US</td>
<td>United States of America</td>
</tr>
<tr>
<td>VN</td>
<td>Viet Nam</td>
<td>YU</td>
<td>Yugoslavia</td>
<td>ZW</td>
<td>Zimbabwe</td>
</tr>
</tbody>
</table>
HUMAN ESTROGEN RECEPTOR-β

Field of the Invention

This invention pertains to DNA encoding a novel human estrogen receptor-β (hERβ), hERβ polypeptides, and methods for expressing and isolating hERβ. The invention also pertains to methods for using hERβ to identify coactivators and inhibitors as well as tissue-specific estrogens.

Background of the Invention

The physiological response to steroid hormones is mediated by specific interactions of steroids with nuclear receptors, which are ligand-activated transcription factors that regulate the expression of target genes by binding to specific DNA response elements. These receptors comprise (in an aminoterminal-to-carboxyterminal direction) a hypervariable aminoterminal domain that contributes to the transactivation function; a highly conserved DNA-binding domain responsible for receptor dimerization and specific DNA binding; and a carboxyterminal domain involved in ligand-binding, nuclear localization, and ligand-dependent transactivation.

Recently, cDNA was cloned from rat prostate and was shown to have significant homology to a previously isolated rat estrogen receptor cDNA. Kuiper et al., Proc.Natl.Acad.Sci.USA 93:5925, 1996. This receptor was designated ERβ to distinguish it from a previously cloned receptor, ERα. Rat ERβ was shown to be expressed in the prostate, testes, ovary, and thymus, in contrast to ERα, which is most highly expressed in the uterus, breast, liver, and pituitary.

A human ERβ homologue having the aminoterminal sequence Gly-Tyr-Ser has been reported. Mosselman et al., FEBS Letts. 392:49, 1996. This reported sequence lacks an initiator methionine, however; therefore, the complete aminoterminal sequence could not be determined. Thus, the full-length human gene remained unknown and an accurate picture of the
molecular determinants of the transactivation function of authentic hERβ could not be obtained.

Summary of the Invention

The present invention provides nucleic acids encoding a full-length human estrogen receptor-β (hERβL). The nucleic acid sequence of hERβL, which is depicted in Figure 3, SEQ ID NO:1, encodes a receptor having the amino acid sequence depicted in Figure 4, SEQ ID NO:2. hERβL according to the present invention contains 45 amino acids at its amineterminus which were not previously known. These amino acids are believed to contribute to the transcription activation function of the receptor.

hERβL is selectively expressed in the thymus, spleen, ovary, and testes. Accordingly, hERβ can be used to identify co-activator proteins that are involved in estrogen-regulated gene expression, as well to identify tissue-selective estrogens.

The present invention provides isolated polypeptides having the sequence of SEQ ID NO:2 and function-conservative variants thereof which exhibit estrogen-regulated transcriptional activation activity. In a related aspect, the invention encompasses isolated peptides derived from hERβ comprising a sequence corresponding to amino acids 1-45 of SEQ ID NO:2 and function-conservative variants thereof, as explained above. It is believed that this sequence provides at least part of the transactivation function.

The present invention also provides isolated nucleic acids encoding hERβL and hERβL-derived peptides, including the nucleic acid sequence depicted in Figure 3, SEQ ID NO:1 and subfragments thereof encoding peptides which comprise amino acids 1-45, as well as sequence-conservative and function-conservative variants thereof. Also encompassed by the invention are DNA vectors comprising an hERβL-encoding sequence operably linked to a transcription regulatory element and cells comprising these vectors. Methods for producing hERβL-derived
polypeptides include incubating a cell comprising an hERβL-encoding expression vector under conditions that permit expression of one or more hERβ polypeptides. The methods further include: (a) harvesting the cells to produce a cell fraction and a medium fraction; and (b) recovering the polypeptide(s) from the cell fraction, medium fraction, or both.

In another aspect, the invention provides methods for identifying hERβ-interactive compounds, including agonists, antagonists, and co-activator proteins. In one embodiment, the method includes:

(a) contacting purified hERβ with a labeled ligand in the presence of test compounds, to form test reactions, and in the absence of test compounds, to form control reactions;

(b) incubating the test and control reactions under appropriate conditions to achieve specific binding of the labelled ligand to hERβ;

(c) determining the level of binding of the labeled ligand to hERβ in said test and control cultures; and

(d) identifying as a hERβ-interactive compound any compound that reduces the binding of the labeled ligand to hERβ.

Brief Description of the Drawings

Figure 1 is a schematic illustration of the oligonucleotides used for PCR amplification of human estrogen receptor-β (hERβL) cDNA (SEQ ID NO:5 and SEQ ID NO: 6).

Figure 2 is a schematic illustration of the pcDNA3 plasmid containing hERβL cDNA.

Figure 3 is an illustration of the full-length cDNA sequence encoding human estrogen receptor-β (hERβL) (SEQ ID NO:1).

Figure 4 is an illustration of the predicted amino acid sequence of the hERβ polypeptide (SEQ ID NO:2). The first 45 (previously unknown) amino acids are underlined.
Figure 5 is a photographic illustration of an autoradiogram of a 10% SDS-polyacrylamide gel in which hERβ in vitro translation products are resolved. Lane 1, hERβT; lane 2, hERβL produced from a vector encoding a synthetic translation initiation site; lane 3, hERβL produced from a vector encoding the natural hERβ translation initiation sequences.

Figure 6A is a graphic illustration of the transcriptional activation capacity of full-length hERβ (hERβL) and truncated hERβ (hERβT) expressed in HepG2 cells. Cells were transfected with either hERβL or hERβT and co-transfected with a luciferase reporter plasmid containing an estrogen response element (ERE) (ERE.TK.LUC) and a control β-galactosidase plasmid. Cells were incubated in the absence or presence of estradiol, after which luciferase activity was measured and normalized to β-galactosidase activity.

Figure 6B is a graphic illustration of luciferase activity in HepG2 cells transfected with either hERβL or hERβT and co-transfected with a luciferase reporter plasmid lacking an ERE (TK.LUC)

Figure 7A is a graphic illustration of the effect of estradiol stimulation of full-length hERβ (hERβL) and truncated hERβ (hERβT) on NFκB activation in HepG2 cells. Cells were transfected with either hERβL or hERβT and co-transfected with a luciferase reporter plasmid containing three copies of an NFκB binding site (3X-NFκB TK.LUC) and a control β-galactosidase plasmid. Cells were stimulated with interleukin-1b and incubated in the absence or presence of estradiol, after which luciferase activity was measured and normalized to β-galactosidase activity. Figure 7B is a graphic illustration of luciferase activity in cells transfected with either hERβL or hERβT and co-transfected with a luciferase reporter plasmid lacking an NFκB binding site (TK.LUC).

Figure 8 is a graphic illustration of the transcriptional activation capacity of full-length hERβ (hERβL) and truncated hERβ (hERβT) expressed in HAECE-1 human endothelial cells. Cells were transfected with either hERβL or hERβT and co-transfected with a luciferase reporter plasmid
containing an ERE (ERE.TK.LUC) or one lacking an ERE (TK.LUC). Cells were incubated in the absence or presence of estradiol, after which luciferase activity was measured. ERE TK.LUC values were normalized to TK.LUC values and are presented as mean ± S.E. (n = 4).

Figure 9 is a graphic illustration of the effect of increasing doses of estrogens (17-β estradiol or genistein) on the transcriptional activation capacity of full-length hERβ (hERβL) and truncated hERβ (hERβT) expressed in S. cerevisiae. Cells were transformed with either hERβL or hERβT and co-transformed with a β-galactosidase reporter plasmid containing an ERE. Transformed cells were treated with estrogens for 3h and assayed for β-galactosidase activity.

**Detailed Description of the Invention**

Human estrogen receptor-β (hereinafter, hERβ) comprises aminoterminal amino acid residues not previously known. The present invention encompasses isolated, purified, nucleic acids encoding authentic full-length hERβ of 530 amino acid residues and fragments thereof which include nucleic acids encoding amino acids 1-45 of hERβ. The invention also encompasses isolated, purified, polypeptides comprising hERβ and peptides derived therefrom, particularly peptides which include residues 1-45 of hERβ. The invention also provides expression systems in which transcriptionally active hERβ or fragments derived therefrom can be produced, as well as screening methods for identifying hERβ agonists and antagonists (including tissue-specific estrogens and anti-estrogens) as well as hERβ co-activators and inhibitors.

**Isolation and Characterization of the Gene Encoding hERβ**

The present inventors have isolated the cDNA encoding hERβ using the methods outlined below. Human testis Poly A + RNA (1 mg, Clontech, Palo Alto CA) was mixed with 0.5 mg oligo dT primer (GIBCO-BRL, Gaithersburg MD) in a total volume of 10 ml. The mixture was heated at
70°C for 10 minutes, and, after cooling on ice, was supplemented with 500 mM of each deoxynucleoside triphosphate, 1X cDNA synthesis buffer, and 10 mM DTT to a final reaction volume of 20 ml. The mixture was incubated at 42°C for 2.5 minutes and then supplemented with 1-2 units reverse transcriptase ( Gibco-BRL, Gaithersburg MD), after which it was incubated at 45°C for 30 minutes and 50°C for 5 minutes. One-tenth of this mixture (approximately 2 ml) containing the cDNA template was then used in PCR amplification of hERβ using forward and reverse primers as described below.

Alignment of the known rat ERβ sequence ( Kuiper et al., Proc. Natl. Acad. Sci. USA 93:5925, 1996) with that of a human homologue ( Mosselman et al., FEBS Letts. 392:49, 1996) suggested that the human sequence lacked at least the ultimate and penultimate residues at its aminoterminus, as shown below:

Rat: MTFYSPAVMNS . . . (SEQ ID NO:3)
Human: GYSPAVMNS . . . (SEQ ID NO:4)

Based on this information, PCR primers were designed that supplement the human sequence with the two missing aminoterminal residues M and T and with an artificial Kozak translation initiation sequence. The forward primer, having the sequence (SEQ ID NO: 5)
5'-GGAAGCTTGTGACCCATCATGACCGGTAGCCCTGCTGTGATG-3'
and a reverse primer, having the sequence (SEQ ID NO:6)
5'-GGATCTAGACGACGGTCAGACTGAGGGTTCTGG-3'
were used to amplify hERβ sequences in a reaction containing the following components: 2 ml of the cDNA template described above; 1X PCR buffer; 200 mM of each deoxynucleoside triphosphate, 2 units of hot tab polymerase (Amersham, Arlington Heights IL), and 1mg of each of the forward and reverse primers. The reaction mixture was heated to 95°C for 2 minutes, annealed at 52°C for 1 minute, and amplified using 36 cycles of 72°C for 1.5 minutes.
A fragment of approximately 1500 bp in length was produced. The fragment digested with HindIII and XbaI (which cleave at sites present in the forward and reverse primer sequences, respectively, but not in the main body of the amplified cDNA sequence) and cloned into the corresponding sites of the pcDNA3 expression vector (Invitrogen, Carlsbad CA). This asymmetric cloning strategy places the 5' end of hERβ cDNA under the control of the viral CMV promoter in pcDNA3 (Figures 1 and 2). Several insert-containing pcDNA3 clones were identified. Plasmid DNA was prepared from three clones using a plasmid purification kit (Qiagen, Santa Clarita CA) and their insert sequences were determined by the dideoxy termination method. One clone (designated R61010-2.24 or Clone 3) was found to contain an insert with a nucleotide sequence identical to the published hERβ sequence (Mosselman et al., FEBS Letts. 392:49, 1996) and had the following 5' end structure:

\[ \text{M T G Y . . . (SEQ ID NO:7)} \]
\[ \text{CCATC ATG ACC GGC TAT . . . (SEQ ID NO:8)} \]

This clone was designated "truncated hERβ" or hERβT.

To verify the aminoterminal and upstream sequence of human hERβ, two independent approaches were taken, as described below.

1. 10 ml of a human ovary 5'-Stretch cDNA library (Clontech, Palo Alto CA) was mixed with 50 ml of 1X K solution (1X PCR Buffer (GIBCO-BRL, Gaithersburg MD), 2.5 mM MgCl2, 0.5% Tween-20, 100 mg/ml Proteinase K), and the reaction mixture was incubated at 56°C for 2 hours, then at 99°C for 10 minutes. 5 ml of this reaction mixture were then used as template in a nested PCR reaction. For the first round, the forward primer (pDR2 sequencing primer, Clontech, Palo Alto CA) had the sequence 5'-CTGGTAAGTTTAGTCTTTTGTC-3' (SEQ ID NO:9), and the reverse primer (hERβ-specific, designated oligo #12908) had the sequence 5'-GCTTCACACCAAGGACTCTTGTGAG-3' (SEQ ID NO:10). The reaction contained 1X KlenTaq PCR reaction buffer (40 mM Tricine-KOH, 15 mM KOAc, 3.5 mM Mg(OAc)2, 75 mg/ml bovine serum albumin);
0.2 mM of each dNTP; 0.2 mM of each of the above primers, and 1 unit of Klentaq Polymerase Mix (Clontech, Palo Alto CA). Touchdown PCR conditions were as follows: 5 cycles of 94°C for 2 seconds and 72°C for 4 minutes, followed by 30 cycles of 94°C for 2 seconds and 67°C for 3 minutes.

Excess nucleotides and primers were removed from first round PCR reactions by purification over Wizard PCR columns (Promega, Madison WI). A second round PCR reaction was then performed using 2 ml of the purified first-round reaction mixture. For the second round, the forward primer was the pDR2 sequencing primer shown above, and the reverse primer had the sequence 5'-'GTTGGCCACAACACATTGATGTGCTG-3' (hERβ-specific, designated oligo #13871) (SEQ ID NO:11). The PCR reaction and cycling conditions were identical to those employed in the first round. The products were cloned into pCR2.1 (Invitrogen) and three resulting clones were sequenced. All three clones (designated L1, L2, and L3) contained hERβ inserts of different lengths, all of which were homologous to hERβ and to each other.

(2) A Marathon Ready thymus cDNA kit (Clontech) for 5' rapid amplification of cDNA ends (RACE) was also used to isolated hERβ 5' clones. In the first round of a nested PCR reaction, 5 ml of human thymus Marathon-ready cDNA (Clontech) was used as template. The forward primer had the sequence 5'-CCATCCGAAATACGCTAGCTATAAGGC-3' (Adaptor primer 1, Clontech) (SEQ ID NO:12), and the reverse primer had the sequence 5'-GCTTCACACCAAAGGACTCTTTTGGAG-3' (hERβ-specific, designated oligo #12908) (SEQ ID NO:10). The PCR reaction and cycling conditions were identical to those described in (1) above.

Excess nucleotides and primers were removed from the first round PCR reactions by purification over Wizard PCR columns (Promega). A second round PCR reaction was performed using 2 ml of the purified first round reaction. For the second round, the forward primer had the sequence 5'-ACTCAGACAGGCTCGAGCGGC-3' (nested adaptor primer 2,
Clontech) (SEQ ID NO:13), and the reverse primer had the sequence 5'-GTTGGCCACACACATTTGGGCTTG-3' (hERβ-specific, designated oligo #13871) (SEQ ID NO:11). The second round PCR reaction and cycling conditions were identical to those employed in the first round. The products were cloned into the pCR2.1 vector and two clones were sequenced. The two clones contain insert sequences of different lengths that are homologous to hERβ, to each other, and to the sequences isolated from a human ovary cDNA library as described above.

All of the hERβ sequences isolated by methods (1) and (2) above contained 110 nucleotides corresponding to hERβT sequences, as well as 228 additional nucleotides at the 5' end (Figure 3).

The hERβ cDNA sequence determined from these clones contained several important differences from the previously known human sequence. First, the third amino acid of the previous sequence was found to be F and not G (see above). Second, the methionine residue at the aminoterminus of the previous sequence was found not to be the initiator (i.e., true aminoterminal) residue. Rather, the authentic full-length hERβ cDNA sequence encodes a polypeptide having 530 residues, the first 45 of which are not found in the previously known human sequence (Figure 4). The sequence appears to be quite homologous to rat ERβ; however, this reading frame was not identified previously (Kuiper et al., Proc.Natl.Acad.Sci.U.SA 93:5925, 1996). Furthermore, an optimal Kozak translation initiation sequence is found upstream of the newly discovered initiator methionine codon. A termination codon was identified 63 nucleotides upstream to the authentic ATG initiator codon in the same reading frame.

The cDNA encoding authentic full-length hERβ was cloned into pCDNA3 under the control of the CMV promoter; this expression vector was designated "long hERβ" or hERβL.
**Synthesis of full-length hERβ and truncated hERβ**

To examine the natural start site for translation of hERβ, three plasmids were subjected to coupled transcription-translation, encoding hERβT (with a synthetic upstream translation initiation sequence), hERβL (with a synthetic upstream translation initiation sequence), and hERβL containing 93 nucleotides of its native upstream sequence (the entire sequence shown in Figure 3). The plasmids were transcribed and translated using the TNT T7 Coupled Reticulocyte Lysate System (Promega #L4610). Circular plasmid DNA was purified using Qiagen Maxi-Kit #12362. 2mg of the DNA was transcribed and translated in a single reaction in the presence of [35S]-methionine (New England Nuclear, Boston MA). The translation products were resolved on a 10% SDS polyacrylamide gel and were visualized by autoradiography (Figure 5).

The resulting translation products of both hERβL products were of similar size (~63 kDa), and the hERβT product was appropriately shorter (~56 KDa). This indicates that the initiator ATG most likely utilized in vivo is the ATG at position 94-96. Utilization of a further upstream ATG is unlikely because of a termination codon in-fram with the presumed start site. Confirmation of the authentic start site is achieved by subjecting hERβ polypeptides to aminoterminal sequencing.

**Functional differences between full-length hERβ and truncated hERβ**

The experiments described below were performed to evaluate the transcription activation properties of full-length hERβ according to the present invention and to compare it with that of truncated hERβ. hERβL and hERβT were expressed in parallel in different cell types and tested for their ability to transactivate reporter genes containing estrogen response elements (EREs). Alternatively, hERβL and hERβT may be expressed in host cells containing endogenous estrogen-responsive genes and the estrogen-mediated activation of the endogenous genes is measured.
(i) HepG2 Cells:

HepG2 cells (ATCC) were transfected in parallel with either pcDNA3-hERβL or pcDNA3-hERβT using the calcium phosphate co-precipitation method. Cells were co-transfected with a reporter plasmid containing a luciferase gene preceded by either an ERE upstream of the thymidine kinase (TK) basal promoter, or the TK basal promoter alone. Cells also received a plasmid encoding β-galactosidase under the control of an RSV promoter, which was used to correct for variation in DNA uptake. Five hours after transfection, cells were incubated with or without 10-6M 17-β estradiol for 20 hours, after which cell extracts were prepared. Luciferase activity was measured by a chemiluminescent method using the Promega luciferase assay system, and β-galactosidase activity was measured by Galactolight (Tropix, Inc., Bedford MA); luciferase activity was then normalized to β-galactosidase activity.

The results shown in Figure 6A indicate that, in the presence of estradiol, hERβT caused a 2-fold stimulation of ERE activity. By contrast, hERβL under the same conditions caused a 6-fold stimulation of ERE activity. Thus, hERβL is about 3-fold more active than hERβT in this circumstance.

In a separate experiment, HepG2 cells were transfected with hERβL or hERβT as above, but the reporter gene consisted of three copies of an NFκB binding site upstream of the TK basal promoter. Transfected cells were incubated with or without interleukin-1b (IL-1b) to activate NFκB and/or with estradiol prior to luciferase determination. The results shown in Figure 7 indicate that hERβL was capable of attenuating the IL-1b-mediated NFκB transcriptional activation (to an extent similar to that observed with hERα), while hERβT exhibited no inhibitory activity.

(ii) Human endothelial cells:

HAEC-T-1 cells (a clonal immortalized human aortic endothelia cell line derived by infection with Ad5 ori-SV40 ts A209) were transfected with pcDNA3hERβT or pcDNA3-hERβL and ERE-luciferase plasmids by
electroporation. After 4 hours, the cells were treated overnight with or without 100 nM 17-β estradiol prior to luciferase activity measurements. The results shown in Figure 8 indicate that hERβL is 2-3 times more active than hERβT in activating the ERE-reporter gene in the presence of estradiol.

In independent experiments, cells transfected under identical conditions were monitored for their levels of estrogen receptors using a ligand binding assay. The results indicate that the increased activity of hERβL relative to hERβT is not due to an increase in receptor number or stability, and, further, that the 2-3 fold increment measured in the above experiment may be an underestimate of the true transactivational capacity of hERβ.

(iii) Yeast:

S. cerevisiae strain BJ2168 (Yeast Genetic Stock Center, Berkeley CA) was co-transformed with an ERE-LacZ reporter plasmid (designated YRpE2) and yeast vectors expressing either hERβL or hERβT under the control of the yeast triose phosphate isomerase promoter in the yeast pYX242 vector (R&D Systems, Minneapolis MN). Transformed cells were grown in selective medium for 24 hours, after which they were treated in the presence or absence of increasing concentrations of either 17-β estradiol or the phytoestrogen Genistein (Research Biochemical International, Natick MA) for 3 hours prior to determination of β-galactosidase activity. The dose-response results shown in Figure 9 indicate that the maximal level of estrogen-stimulated LacZ expression was 2-fold higher in hERβL-transformed cells relative to hERβT-transformed cells.

**DNA, Vectors, and Expression Systems**


The present invention encompasses purified, isolated, nucleic acid sequences encoding hERβ, including, e.g., the nucleotide sequence depicted in Figure 3 SEQ ID NO:1 and subfragments derived therefrom, including without limitation transcriptional activation-competent fragments. An "isolated" or "purified" nucleic acid is a nucleic acid or polypeptide that is removed from its original environment (for example, its natural environment if it is naturally occurring). An isolated nucleic acid or polypeptide contains less than about 50%, preferably less than about 75%, and most preferably less than about 90%, of the cellular components with which it was originally associated.

A nucleic acid that is "derived from" an hERβ sequence is a nucleic acid sequence that corresponds to a region of the sequence, sequences that are homologous or complementary to the sequence, and "sequence-conservative variants" and "function-conservative variants". Sequence-conservative variants are those in which a change of one or more nucleotides in a given codon position results in no alteration in the amino acid encoded at that position. Function-conservative variants are those in which the amino acid sequence of hERβ has been changed without altering the overall conformation and transcriptional activation function of the hERβ polypeptide, including, but not limited to, replacement of an amino acid with one having similar physico-chemical properties (such as, for example, acidic, basic, hydrophobic, and the like). A large number of candidate function-conservative hERβ variants, as well as fragments of hERβ that
retain transcriptional activation activity, can be prepared using routine recombinant DNA manipulations as well as random or site-directed mutagenesis techniques. Furthermore, hERβ-derived variants or fragments that exhibit transcriptional activation activity can be identified using routine experimentation by employing the methods described herein, e.g., by co-expression with an appropriate reporter gene followed by measurement of reporter gene transcription in the presence and absence of an estrogen.

In another embodiment, the present invention encompasses isolated, purified, nucleic acids comprising nucleotides 94-229 of the sequence depicted in Figure 3, SEQ ID NO:1, which encode amino acids 1-45 of hERβ, and sequence-conservative variants thereof.

The nucleic acids of the present invention include purine- and pyrimidine-containing polymers of any length, either polyribonucleotides or polydeoxyribonucleotides or mixed polyribo-polydeoxyribo nucleotides. This includes single- and double-stranded molecules, i.e., DNA-DNA, DNA-RNA and RNA-RNA hybrids, as well as "protein nucleic acids" (PNA) formed by conjugating bases to an amino acid backbone. This also includes nucleic acids containing modified bases.

The nucleic acids may be isolated directly from cells. Alternatively, PCR can be used to produce the nucleic acids of the invention, using either chemically synthesized strands or genomic material as templates. Primers used for PCR can be synthesized using the sequence information provided herein and can further be designed to introduce appropriate new restriction sites, if desirable, to facilitate incorporation into a given vector for recombinant expression.

The nucleic acids of the present invention may be flanked by natural regulatory sequences, or may be associated with heterologous sequences, including promoters, enhancers, response elements, signal sequences, polyadenylation sequences, introns, 5'- and 3'- noncoding regions, and the like. The nucleic acids may also be modified by many means known in the art. Non-limiting examples of such modifications include methylation,
"caps", substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoroamidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.). Nucleic acids may contain one or more additional covalently linked moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), intercalators (e.g., acridine, psoralen, etc.), chelators (e.g., metals, radioactive metals, iron, oxidative metals, etc.), and alkylators. PNAs are also included. The nucleic acid may be derivatized by formation of a methyl or ethyl phosphotriester or an alkyl phosphoramidate linkage. Furthermore, the nucleic acid sequences of the present invention may also be modified with a label capable of providing a detectable signal, either directly or indirectly. Exemplary labels include radioisotopes, fluorescent molecules, biotin, and the like.

The invention also provides nucleic acid vectors comprising hERβ-encoding sequences or derivatives or fragments thereof. A large number of vectors, including plasmid and fungal vectors, have been described for replication and/or expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple cloning or protein expression. The encoded hERβ-derived polypeptides may be expressed by using many known vectors, such as pUC plasmids, pET plasmids (Novagen, Inc., Madison, WI), or pRSET or pREP (Invitrogen, San Diego, CA), and many appropriate host cells, using methods disclosed or cited herein or otherwise known to those skilled in the relevant art. The particular choice of vector/host is not critical to the practice of the invention.

Recombinant cloning vectors will often include one or more replication systems for cloning or expression, one or more markers for selection in the host, e.g. antibiotic resistance, and one or more expression cassettes. The inserted hERβ-encoding sequences may be synthesized by
standard methods, isolated from natural sources, or prepared as hybrids, etc. Ligation of the hERβ-encoding sequences to transcriptional regulatory elements and/or to other amino acid coding sequences may be achieved by known methods. Suitable host cells may be transformed/transfected/infected as appropriate by any suitable method including electroporation, CaCl2 mediated DNA uptake, viral vector-mediated DNA delivery, fungal infection, microinjection, microprojectile, or other established methods.

Appropriate host cells included bacteria, archebacteria, fungi, especially yeast, and plant and animal cells, especially mammalian cells. Of particular interest are E. coli, B. Subtilis, Saccharomyces cerevisiae, Saccharomyces carlsbergensis, Schizosaccharomyces pombi, SF9 cells, C129 cells, 293 cells, Neurospora, and HepG2 cells, CHO cells, COS cells, HeLa cells, and immortalized mammalian myeloid and lymphoid cell lines.

Preferred replication systems include M13, ColE1, SV40, baculovirus, lambda, adenovirus, and the like. A large number of transcription initiation and termination regulatory regions have been isolated and shown to be effective in the transcription and translation of heterologous proteins in the various hosts. Examples of these regions, methods of isolation, manner of manipulation, etc. are known in the art. Under appropriate expression conditions, host cells can be used as a source of recombinantly produced hERβ-derived peptides and polypeptides.

Advantageously, vectors may also include a transcription regulatory element (i.e., a promoter) operably linked to the hERβ portion. The promoter may optionally contain operator portions and/or ribosome binding sites. Non-limiting examples of bacterial promoters compatible with E. coli include: β-lactamase (penicillinase) promoter; lactose promoter; tryptophan (trp) promoter; arabinose BAD operon promoter; lambda-derived PI promoter and N gene ribosome binding site; and the hybrid tac promoter derived from sequences of the trp and lac UV5 promoters. Non-limiting examples of yeast promoters include triose phosphate isomerase promoter, 3-
phosphoglycerate kinase promoter, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter, galactokinase (GAL1) promoter, galactoepimerase promoter, and alcohol dehydrogenase (ADH) promoter. Suitable promoters for mammalian cells include without limitation viral promoters such as that from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus (ADV), and bovine papilloma virus (BPV). Mammalian cells may also require terminator sequences and poly A addition sequences and enhancer sequences which increase expression may also be included; sequences which cause amplification of the gene may also be desirable.

Furthermore, sequences that facilitate secretion of the recombinant product from cells, including, but not limited to, bacteria, yeast, and animal cells, such as secretory signal sequences and/or prohormone pro region sequences, may also be included. These sequences are well described in the art.

Nucleic acids encoding hERβ-derived polypeptides may also be introduced into cells by recombination events. For example, such a sequence can be introduced into a cell, and thereby effect homologous recombination at the site of an endogenous gene or a sequence with substantial identity to the gene. Other recombination-based methods such as nonhomologous recombinations or deletion of endogenous genes by homologous recombination may also be used.

The nucleic acids of the present invention find use as templates for the recombinant production of hERβ-derived peptides or polypeptides.

hERβ-derived polypeptides

The present invention encompasses purified hERβ-derived polypeptides comprising amino acids 1-45 of hERβ and further comprising all or part of the amino acid sequence depicted in Figure 4, SEQ ID NO:2, and function-conservative variants thereof, i.e., variants that exhibit estrogen-induced transcriptional activation activity. Also encompassed by
the invention are peptides comprising amino acids 1-45 of SEQ ID NO:2 and function-conservative variants thereof.

Nucleic acids comprising hERβ-coding sequences can be used to direct the expression of hERβ-derived polypeptides in intact cells or in cell-free translation systems. The known genetic code, tailored if desired for more efficient expression in a given host organism, can be used to synthesize oligonucleotides encoding the desired amino acid sequences. The phosphoramidite solid support method of Matteucci et al., 1981, J. Am. Chem. Soc. 103:3185, the method of Yoo et al., 1989, J. Biol. Chem. 764:17078, or other well known methods can be used for such synthesis. The resulting oligonucleotides can be inserted into an appropriate vector and expressed in a compatible host organism.

The polypeptides of the present invention, including function-conservative variants of the disclosed hERβ sequences, may be isolated from wild-type or mutant human cells, or from heterologous organisms or cells (including, but not limited to, bacteria, fungi, insect, plant, and mammalian cells) into which an hERβ-derived protein-coding sequence has been introduced and expressed. Furthermore, the polypeptides may be part of recombinant fusion proteins.

Polypeptides may be chemically synthesized by commercially available automated procedures, including, without limitation, exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis. The polypeptides are preferably prepared by solid phase peptide synthesis as described by Merrifield, 1963, J. Am. Chem. Soc. 85:2149.

"Isolation" or "purification" of an hERβ-derived polypeptide refers to the isolation of the polypeptide in a form that allows its transcriptional activation activity to be measured without interference by other components of the cell in which the polypeptide is expressed. Methods for polypeptide purification are well-known in the art, including, without limitation, preparative disc-gel electrophoresis, isoelectric focusing, HPLC,
reversed-phase HPLC, gel filtration, ion exchange and partition chromatography, and countercurrent distribution. For some purposes, it is preferable to produce the polypeptide in a recombinant system in which the hER\(\beta\)-derived protein contains an additional sequence tag that facilitates purification, such as, but not limited to, a polyhistidine sequence. The polypeptide can then be purified from a crude lysate of the host cell by chromatography on an appropriate solid-phase matrix. Alternatively, antibodies produced against an hER\(\beta\)-derived protein or against peptides derived therefrom can be used as purification reagents. Other purification methods are possible.

The present invention also encompasses derivatives and homologues of hER\(\beta\)-encoded polypeptides. For some purposes, nucleic acid sequences encoding the peptides may be altered by substitutions, additions, or deletions that provide for functionally equivalent molecules, i.e., function-conservative variants. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of similar properties, such as, for example, positively charged amino acids (arginine, lysine, and histidine); negatively charged amino acids (aspartate and glutamate); polar neutral amino acids; and non-polar amino acids.

The isolated polypeptides may be modified by, for example, phosphorylation, sulfation, acylation, or other protein modifications. They may also be modified with a label capable of providing a detectable signal, either directly or indirectly, including, but not limited to, radioisotopes and fluorescent compounds.

**hER\(\beta\)-specific Antibodies**

The present invention encompasses antibodies that specifically recognize hER\(\beta\)-derived peptides and polypeptides, including without limitation antibodies that recognize hER\(\beta\) but not, e.g., hERA, and those that recognize hER\(\beta\)L but not hER\(\beta\)T. Such hER\(\beta\)-specific antibodies can be used conventionally, e.g., as diagnostic reagents or as reagents for purification
of hER\(\beta\)-derived polypeptides. Other uses include immunocytochemical localization of hER\(\beta\); gel shift assays; and "pull-down" experiments to identify protein co-activators associated with hER\(\beta\).

hER\(\beta\)-specific antibodies according to the present invention include polyclonal and monoclonal antibodies. The antibodies may be elicited in an animal host by immunization with hER\(\beta\) immunogenic components or may be formed by in vitro immunization (sensitization) of immune cells. The immunogenic components used to elicit the production of antibodies may be isolated from any cell source or may be chemically synthesized. The antibodies may also be produced in recombinant systems programmed with appropriate antibody-encoding DNA. Alternatively, the antibodies may be constructed by biochemical reconstitution of purified heavy and light chains. The antibodies include hybrid antibodies (i.e., containing two sets of heavy chain/light chain combinations, each of which recognizes a different antigen), chimeric antibodies (i.e., in which either the heavy chains, light chains, or both, are fusion proteins), and univalent antibodies (i.e., comprised of a heavy chain/light chain complex bound to the constant region of a second heavy chain). Also included are Fab fragments, including Fab' and F(ab)2 fragments of antibodies. Methods for the production of all of the above types of antibodies and derivatives are well-known in the art. For example, techniques for producing and processing polyclonal antisera are disclosed in Mayer and Walker, 1987, Immunochemical Methods in Cell and Molecular Biology, (Academic Press, London). The general methodology for making monoclonal antibodies by hybridomas is well known. Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., Schreier et al., 1980, Hybridoma Techniques. Panels of monoclonal antibodies produced against hER\(\beta\) epitopes can be screened for various properties; i.e., for isotype, epitope affinity, etc.
Antibodies against hERβ-derived immunogenic components can be used, unlabeled or labeled by standard methods, as the basis for immunoassays. The particular label used will depend upon the type of immunoassay used. Examples of labels that can be used include but are not limited to radiolabels such as 32P, 125I, 3H and 14C; fluorescent labels such as fluorescein and its derivatives, rhodamine and its derivatives, dansyl and umbelliferone; chemiluminescers such as luciferia and 2,3-dihydrophthal-azinediones; and enzymes such as horseradish peroxidase, alkaline phosphatase, lysozyme and glucose-6-phosphate dehydrogenase.

**Applications**

The methods and compositions of the present invention can be used to identify compounds that interact with hERβ, either to activate or to inhibit its transcriptional activation function. Such compounds include, without limitation, co-activator proteins, as well as estrogens and other steroids, steroid-like molecules, or non-steroid-like molecules that act as agonists or antagonists. Screening methods can also be used to identify tissue-specific estrogens.

Identification of hERβ-interactive compounds can be achieved by cell-free or cell-based assays. In one set of embodiments, purified hERβ is contacted with a labelled ligand, such as, e.g., 17β estradiol, in the presence of test compounds to form test reactions, and in the absence of test compounds to form control reactions. The labelled moiety may comprise a radiolabel (such as, e.g., 3H or 125I) or a fluorescent molecule. Incubation is allowed to proceed for a sufficient time and under appropriate conditions to achieve specific binding, after which binding of labelled estradiol to hERβ is measured (by monitoring, e.g., radioactivity, fluorescence, or fluorescence polarization). In one embodiment, hERβ produced in E. coli (as described in Example 1 below) is adsorbed to the wells of a microtiter dish and incubated with [3H]-17β estradiol in the absence or presence of test compounds (see, e.g., Example 2 below).
Alternatively, soluble receptor is incubated with the labelled ligand in the absence or presence of test compounds, and bound ligand is separated from free ligand, either by filtration on glass fiber filters or by using dextrancoated charcoal. See, e.g., Hulme, ed., Receptor-ligand Interactions: A Practical Approach, IRL Press, NY, 1992).

Whole cell binding assays may also be used in which bound ligand is separated from free ligand by rinsing. Cells used in these assays may either contain endogenous receptor, or may overexpress the receptor subsequent to stable or transient transfection or infection of an hER\(\beta\) gene or cDNA.

Non-limiting examples of suitable cells include COS cells, Hela cells, CHO cells, human umbilical vein endothelial cells (HUVEC), and yeast. Once a compound has been identified as an hER\(\beta\)-interactive compound by its binding activity, further in vivo and in vitro tests may be performed to determine the nature and extent of activity, i.e., as an agonist or antagonist (see below).

hER\(\beta\)-interactive compounds may also be identified using cell-based assays that measure transcriptional activation or suppression of endogenous or transfected estrogen-responsive genes. For example, agonists (such as, e.g., 17\(\beta\)-estradiol) block interleukin-1b induction of endogenous E-selectin in primary human umbilical vein endothelial cells (HUVEC) that express hER\(\beta\). Antagonists (such as, e.g., ICI-182780) block the agonist activity of 17\(\beta\)-estradiol. Non-limiting examples of other suitable endogenous estrogen-responsive promoter elements include those that regulate endothelin-1 (ET-1); HDL receptor (scavenger receptor type II); and enzymes involved in coagulation and fibrinolysis (such as, e.g., plasminogen activator inhibitor-1 and complement C3). Any promoter element that responds to estrogen may be used as an appropriate target, including, e.g., the NFkB binding site or the apolipoprotein A1 gene enhancer sequence.

In one set of embodiments, appropriate host cells are transfected with an expression vector encoding hER\(\beta\) and the transfectants are
incubated with or without estradiol in the presence or absence of test compounds. hERβ activity is assessed by measuring transcriptional activation of the target sequence. This may be achieved by detection of mRNA (using, e.g., Northern blot analysis) and/or by detection of the protein (using, e.g., immunoassays or functional assays). If activation of the target sequence initiates a biochemical cascade, downstream biological events may also be measured to quantify hERβ activity. hERβ-interactive compounds are identified as those that positively or negatively influence target sequence activation.

In another set of embodiments, appropriate host cells (preferably, bacterial or yeast cells) are co-transfected with an expression vector encoding hERβ and a reporter plasmid containing a reporter gene downstream of one or more estrogen response elements (EREs). Transfected cells are incubated with or without estradiol in the presence of absence of test compounds, after which hERβ activity is determined by measuring expression of the reporter gene. In a preferred embodiment, hERβ activity is monitored visually. Non-limiting examples of suitable reporter genes include luciferase, chloramphenicol acetyl transferase (CAT), and green fluorescence protein.

Preferably, the methods of the present invention are adapted to a high-throughput screen, allowing a multiplicity of compounds to be tested in a single assay. Candidate estrogens and estrogen-like compounds include without limitation diethylstilbestrol, genistein, and estrone. Other hERβ-interactive compounds may be found in, for example, natural product libraries, fermentation libraries (encompassing plants and microorganisms), combinatorial libraries, compound files, and synthetic compound libraries. For example, synthetic compound libraries are commercially available from Maybridge Chemical Co. (Trevillet, Cornwall, UK), Comgenex (Princeton, NJ), Brandon Associates (Merrimack, NH), and Microsource (New Milford, CT). A rare chemical library is available from Aldrich Chemical Company, Inc. (Milwaukee, WI). Alternatively, libraries of natural compounds in the
form of bacterial, fungal, plant and animal extracts are available from, for example, Pan Laboratories (Bothell, WA) or MycoSearch (NC), or are readily producible. Additionally, natural and synthetically produced libraries and compounds are readily modified through conventional chemical, physical, and biochemical means (Blondelle et al., TibTech 14:60, 1996). hERβ binding assays according to the present invention are advantageous in accommodating many different types of solvents and thus allowing the testing of compounds from many sources.

Compounds identified as hERβ agonists or antagonists using the methods of the present invention may be modified to enhance potency, efficacy, uptake, stability, and suitability for use in therapeutic applications, etc. These modifications are achieved and tested using methods well-known in the art.

Description of the Preferred Embodiments

The following examples are intended to illustrate the present invention without limitation.

Example 1: High-level Expression of Human hERβ in E. coli

Human hERβ according to the present invention is overexpressed in E. coli strain BL21(DE3) using, for example, the pET15B vector. A 10-ml overnight culture is used to inoculate 1 liter LB medium containing 100 mg/ml ampicillin. Cultures are grown at 37°C and then induced by the addition of 1 mM IPTG. After an additional incubation for 2h at 25°C, cells are harvested by centrifugation at 10,000 X G for 30 minutes and resuspended in 100 ml of a buffer containing 50 mM Tris-HCl, pH 7.4 -150 mM NaCl. Cells are lysed using a French press, and insoluble material is pelleted by centrifugation. The supernatant solution is recovered and stored at -70°C.
Example 2: Estrogen Receptor-β Ligand Binding Assay

For determining the ability of a particular compound to bind hERβ, 100 ml of the receptor preparation described in Example 1 above, diluted in assay buffer (Gibco's phosphate buffered saline (Gibco #14200-075) supplemented with 1 mM EDTA), is added to each well of a high-binding masked microtiter plate (Wallac #1450-511, Gaithersburg MD). 10 ml of test compound (or vehicle) and 10 ml of [3H]-17β-estradiol are added to each well, and the plate is incubated at room temperature for 4-6 hours. Unbound material is aspirated, and the plate is washed three times with 300 ml of assay buffer. Then, 150 ml of scintillation cocktail (Optiphase Supermix, Wallac #1200-439) is added per well, and the plate is sealed and agitated for at least 5 min. Bound radioactivity is measured by scintillation counting.

Test compounds are initially tested at a concentration of 1.5 mg/ml (approximately 5 mM for a compound having a molecular mass of 300). Positive compounds are then re-tested at a number of different concentrations to determine the IC50.

Data are expressed as percent inhibition of specific binding. Exploratory data analysis (EDA) is performed on raw data to check for non-normality and non-homogeneity of variance. The maximum likelihood Box-Cox transformation, which maximizes the normality, homogeneity of variance, and goodness of fit of the data, is then obtained. Based on the result, the appropriate transformation of the data (no transformation, square root transformation, or logarithmic transformation) is used for model fitting. The Huber M-estimator is used to down weight any outlying transformed observations for analysis of variance and dose-response curve fitting.

For ANOVA, multiple comparisons LSD p-values are computed. Retransformed summary statistics (mean, s.d, s.e.m.) are obtained for each treatment group.

For dose-response curve fitting, a four parameter logistic model on the transformed, weighted data are fit. The four parameters are min, max,
slope, and ED50, where ED50 is defined as the dose which corresponds to midway between the estimated max and min. All of the parameters and confidence intervals are re-transformed back to the original units of the data. A further transformation into percent inhibition (using estimated min and max) is performed.

Using this assay, the following values were obtained for reference compounds:

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC50</th>
<th>95% confidence limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>17β-estradiol</td>
<td>6.7 nM</td>
<td>6 - 7.5 nM</td>
</tr>
<tr>
<td>diethylstilbestrol</td>
<td>21 nM</td>
<td>14 - 31 nM</td>
</tr>
<tr>
<td>genistein</td>
<td>1.6 nM</td>
<td>1.4 - 1.8 nM</td>
</tr>
</tbody>
</table>

All patents, applications, articles, publications, and test methods mentioned above are hereby incorporated by reference.

Many variations of the present invention will suggest themselves to those skilled in the art in light of the above detailed description. Such obvious variations are within the full intended scope of the appended claims.
Claims:

1. An isolated nucleic acid comprising the sequence depicted in Figure 1, SEQ ID NO:1.

2. A nucleic acid as defined in claim 1, wherein said nucleic acid is DNA.

3. A nucleic acid as defined in claim 1, wherein said nucleic acid is RNA.

4. A recombinant DNA vector comprising a sequence as defined in claim 1.

5. A recombinant DNA vector comprising a sequence as defined in claim 1 operably linked to a transcription regulatory element.

6. A cell comprising a DNA vector as defined in claim 5, wherein said cell is selected from the group consisting of bacterial, fungal, plant, insect, and mammalian cells.

7. A method for producing a polypeptide, said method comprising incubating a cell as defined in claim 6 under conditions that permit expression of one or more polypeptides encoded by said nucleic acid.

8. A method as defined in claim 7, further comprising:
   (a) harvesting said incubated cells to produce a cell fraction and a medium fraction; and
   (b) recovering said one or more polypeptides from said cell fraction, said medium fraction, or both.

9. A purified isolated nucleic acid encoding the amino acid sequence depicted in Figure 1 SEQ ID NO:2.

10. A nucleic acid as defined in claim 9, wherein said nucleic acid is DNA.

11. A nucleic acid as defined in claim 9, wherein said nucleic acid is RNA.

12. A recombinant DNA vector comprising a sequence as defined in claim 9.
13. A recombinant DNA vector comprising a sequence as defined in claim 9 operably linked to a transcription regulatory element.

14. A cell comprising a DNA vector as defined in claim 13, wherein said cell is selected from the group consisting of bacterial, fungal, plant, insect, and mammalian cells.

15. A method for producing a polypeptide, said method comprising incubating a cell as defined in claim 14 under conditions that permit expression of one or more polypeptides encoded by said nucleic acid.

16. A method as defined in claim 15, further comprising:
   (a) harvesting said incubated cells to produce a cell fraction and a medium fraction; and
   (b) recovering said one or more polypeptides from said cell fraction, said medium fraction, or both.

17. A purified polypeptide comprising a sequence selected from the group consisting of the sequence depicted in Figure 1 SEQ ID NO:2 and function-conservative variants thereof.

18. A purified polypeptide comprising amino acids 1-45 of the sequence depicted in Figure 1 SEQ ID NO:2.

19. A method for identifying hERβ-interactive compounds, said method comprising:
   (a) contacting purified hERβ with a labelled ligand in the presence of test compounds, to form test reactions, and in the absence of test compounds, to form control reactions;
   (b) incubating said test and control reactions under appropriate conditions to achieve equilibrium binding of said labelled ligand to hERβ;
   (c) determining the level of binding of said labelled ligand to hERβ in said test and control cultures; and
   (d) identifying as a hERβ-interactive compound any compound that reduces the binding of said labelled ligand to hERβ.
20. A method as defined in claim 19, wherein said ligand is 17-β estradiol.

21. A method as defined in claim 19, wherein said hERβ-interactive compound is an agonist.

22. A method as defined in claim 19, wherein said hERβ-interactive compound is an antagonist.

23. An antibody that specifically recognizes hERβ.
FIG. 1
CAGCCATTATCTTTGCCCCACGATCTTGGAGAACATTATATGACCTTTTGTGCCCTTTCTCT 60
TGCAAGGTGTTCCTCACGCTATATCTCAAGACATGGATATAAAAACTCACCATTCTAGC 120
CTTAATTCTCCTTCCCTTCTCAACTGCTCAATCCATCTTTACCCCTGAGCAGGCTTCC 180
ATATACATACCTCTTCTCTTATGTAGACAGCCACCAGTAATATCCAGGCACTGAGACATTCTAT 240
AGCCCCGTGTGATGAATTTACACGATTTCCACAGAATGCTCATAACTTTGGAAAGGTGGCT 300
GTCGGCAGACACACAGCAATGCCCACCTGGGCAACACCTGGCAGCCTCTTCTCTTTA 360
GTGGTCCATCGCAGTTATTATCATTCTGTATGCGGAACCTCAAAGATCTCCTGCTGTAAG 420
GCAAGATGCTGTAAGACACACCTTACTTACTGTAAACAGAGAGACACTGAAAGGAGGTA 480
GGGAAACGGTTGCGCCAGCCTTGGTTACTGGTCTGAGGATCTGAAGAGGATGTCCTCTGC 540
GCTGTCTGCAGCGGATTTACGCATCGGTAATATCACTATATGAGCTGCTGTGCTGTAAGGATGT 600
AAGGCCCTTTTTAATAAAAAGAAGCATTCAAGGACATAATGATTATAATTGTTGACGCTACAAT 660
CAGTGTACACATTGAATACCCGGCGCAAGAGTCCTGCGCCAGGCTTGCCGCAGCTGAGGT 720
TACGAGCTGGAATGGTGAATGTTGCGCTCCCAGAGAGAGATGTTGCTCCGGCTCTTG 780
CGGAGACAGAAGATGTCGCCAGACAGACTGCTACTGTGCCGCAAGGCAAGAAGATGGGC 840
GGGCCAGCGCCAGTGCAGGGAACCTGCTGTGGACGCTGCCAGCCAGCTGAGCTATGT 900
CTCACCCCTCTCGGGAGCTGAGCGGCCCAGCAGCTGCTGTGCTAGCAGCCCGCCAAGCTGGCCCTCTC 960
ACCGAGGCCTCCATGATGATGCTCCCTGACCAGATGTTGGCCGACAAGAGGTGTTGTAACACAT 1020
ATCAGCTGGCGCAAGAAGATCTCCGGCCTTTGTGAGCTCAAGGCTTCGAAACAGATGGCG 1080
CTCTTTGGAGACGCTTTGGAATGGGATTTAATGATGTTGGCGCTAGTGCTGCCATATTGAC 1140
CACCCGGCAAGCTGCTATCTTTGCTCCACAGATCTTTGCTGACAGGGATGGGAGGGAATGCG 1200
GTGAAGGAATTTCTGGAATCTTTGACATGCTCTGGCAACTACTTTAAGGTTTGTGAGAG 1260
TTAAAACCTCAACAAAGAAATATCCTCTGTTCAAGGCACTGTCTGCTCAATTCCAGT 1320
ATGTACCCCTCTGTCACACGCACCGAGTAGCTGCAAGCAGCCCGGAAAGCTGTGCTACCTTG 1380
CTGAACGCGATGACCATCTTTGGGTGTTGATTGGCGATGCTCCAGAAGGCCATCTCCCAAG 1440
CAGCAATCCATCGCCTGGTAACCTCCTGTGCTCTGCTGCCACGTGCAAGGCTCGAAGGT 1500
AACAAGGGCATGAAACTCCTGCTCAACATGAAGTGCAAAATATGTTGGCTCCAGTGTATGAC 1560
CTGCTGCTGGAGATGTGCAATGGCCACGTGCTGGGGGTTGCAAGTCCTCCATCAGGGG 1620
TCCGAGTGCAAGGCCAGGAGACAGATTTAAAGGCAAAGAGGCTCCAGAACCACAGCT 1680
CAGTGA 1686

FIG. 3
SUBSTITUTE SHEET (RULE 26)
MDIKNSPSSI NSPSYNCSO SILPLEHSGSI YIPSSYVDSH HFYPAMTEYS 50
PAVMNYSIPS NVTNLEGPG RQTTSPNVLW PTPGHLSPLV VHRQLSHLYA 100
EPQKSPWCEA RSLEHTLPVN RETLKRKVSG NRCAVPVTGP GSKRDAHFCG 150
VCSDYASGYH YGWSCEGCK AFFKRSIQGH NDYICPATNO CTIDKNRRKS 200
CQACRLRKCY EVGMVKGCSR RERCGYRLVR RQRSADEQLH CAGKAKRSGG 250
HAPRVRELLL DALSPEQLVL TLLEAEPHV LISRPAPFT EASMMMSLTK 300
LADKELVHMI SWAKKIGFV ELSLFDVRL LESCMEVLM MGLMWRSDIH 350
PGKLIFAPDL VLDRDEGKCV EGIIFDMML LATTSRFREL KLQHKEYLCV 400
KAMILLNSSM YPLVTATQDA DSSRKLAHLL NAVTDALVWV IAKSGISSQ 450
QSMRLANLLM LLLSHRHASN KGMELLLNMK CKNVPVYDKL LLEMLNAHVL 500
RGCKSSITGS ECSPAEDSKS KEQSONPQSQ 531

FIG. 4
FIG. 6A

17-β ESTRADIOL (10^-6)

- - + - - + +

hum ERβT - - + - + -

hum ERβL - - - + - +

FIG. 6B

17-β ESTRADIOL (10^-6)

- + - - + +

hum ERβT - - + - + -

hum ERβL - - - + - +

REPORTER: ERE TK.LUC
CELLS: HepG2

REPORTER: TK.LUC
CELLS: HepG2

SUBSTITUTE SHEET (RULE 26)
**FIG. 7A**

**REPORTER:** 3X NF-KB TK.LUC  
**CELLS:** HepG2

- **IL-1β (100U/ml)**  
  - **-**  
  - **+**  

- **17β-ESTRADIOL (10⁻⁶ M)**  
  - **-**  
  - **-**  
  - **+**

**% LUC ACTIVITY**

- **NONE**
- **hERα**
- **hERβ¹⁷**
- **hERβL**

**FIG. 7B**

**REPORTER:** TK.LUC  
**CELLS:** HepG2

- **IL-1β (100U/ml)**  
  - **-**  
  - **+**  
  - **+**

- **17β-ESTRADIOL (10⁻⁶ M)**  
  - **-**  
  - **-**  
  - **+**

**% LUC ACTIVITY**

- **NONE**
- **hERα**
- **hERβ¹⁷**
- **hERβL**

**SUBSTITUTE SHEET (RULE 26)**
FIG. 8

- CONTROL
- 100 nM 17-β ESTRADIOL

Luciferase

ER β₁

ER β₂

SUBSTITUTE SHEET (RULE 26)
1/7

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:
   (A) NAME: American Home Products Corporation
   (B) STREET: Five Giralda Farms
   (C) CITY: Madison
   (D) STATE: New Jersey
   (E) COUNTRY: U.S.A.
   (F) POSTAL CODE (ZIP): 07940
   (G) TELEPHONE: (973) 683-2169
   (H) TELEFAX: (973) 683-4117

(ii) TITLE OF INVENTION: Novel Human Estrogen Receptor-B

(iii) NUMBER OF SEQUENCES: 13

(iv) COMPUTER READABLE FORM:
   (A) MEDIUM TYPE: Floppy disk
   (B) COMPUTER: IBM PC compatible
   (C) OPERATING SYSTEM: PC-DOS/MS-DOS
   (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 1686 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CAGCCATTAT ACTTGGCCAC GAATCTTTGA GAACATTATA ATGACCTTTG TGCCCTCTCT  60
TGCAAGGGTG TTTTCAGCTT GCTATCTCAA GACATGGATA TAAAAACCTC ACCATCTAGC 120
CTTAAATTCT CTTCTCTCTA CAACCTGCAGT AAATGAGACT TACCCCTGGA GCAGGCCCTC 180
ATATACATAC TTTGGAGACGC CACCATGATAT GTCAGACCAT GACATCTAT  240
AGGCCTGCTG TGATGGAATTA CAGCATTCCC AGCAATGTCA CTAACCTGGG AGGGGGCCT 300
GGTCGCCAGA CCACAGCCC AAATGTTTGG TGGCCAAACAC CTGGCCACCT TTCTCTTTTA 360
GTTGCTCATC GCCAGTTATT ACAAATGTAT CGGGAACCTC AAAAGAGCTC CTGTTGTGAA 420
GCAAAGATCC TAGAACCACAC TATCCCTGTA AAACAGAGACA CACTGAAAAG AAGTGTAGT 480
GGGAACCGTT GCAGCCAGCCC TGTTACTGTGT CCCAGTTCAAG AGAGGGATGC TCACCTCTGC 540
GCTGCTGCAA GGAGATTGCT ATCCGGGATAT CACTATGGAG TCTGGTGCTG TGAAAGGATG 600
AAGGCGCTTT TTTAAAGAGA CATTCAAGGA CATAATGATT ATATTTGTCC AGCTACAAAT 660
CAGTGACAA TCGATAAAAA CGGCCGCAAG AGCTGCGCAG CCTGCGCAGT TCAGAAAATG 720

SUBSTITUTE SHEET (RULE 26)
2/7

TCGAGGTGG GAATGTTGAA GTGTTGCTCC CGGAGAGAGA GATGTGGGTA CCGCTTGTG  
CGGAGACAGA GAATGCTGCA CGAACAGCTG CACTGTCGG GCAAGGCAAA GAGAAGTGGC  
GCGCAAGCGG CCGAGTGCGG GAAGCTGCTG CTGGACGGCC TGAGCCGGGA CAGCTAGTG  
CTCACCCTTC TTCAGGCTGTA CCGCCTCCCAT GTGCTGATCAG GCGGCCCCAG TGCGCCCTTC  
ACCGAGGCTC CATGATGATG GTCCCTGACC AAGTTGGCCG ACAAGGAGTT GGTACACATG  
ATCGAGCTGGC CAAAGAAGAT TCCCCGCTTT TTCGGAGCTCA GCTCTGTCGA CCAAGTGGCG  
CTCTTGGAGA GCTGTGTGTA GAGGATGTTA ATGATGGGGC TGATGTGGCG CTCAATTGAC  
CACCCCGCGA AAGCTCATCCT TGCTCCAGAT CTGCTTCTGGG CACAGGATGA GGGGAATGC  
GFAAGAAAGA TTCTGGGAAT CTTTGACATG CTCCGGCAGA CTACTTCAGG GTTTCGAGAG  
TFAAAACTCC AACAACAGA ATATCTCTGT GTCAAGGGCA TGATCCTGCT CAATTCGATG  
ATGTACCCTT TGTCAGACGC GGACCAGGAT GCTGACAGCA GCCGGAGCTT GCTCAGCTG  
CGCAACGCGC TGACGCTGCA TTTGGTGGG CGTATTGGCA AGACCGGCTC CTCCCTCCAG  
CACCAATCCA TGGCGCTGCA TAAACCTCCTG ATGCTCTGCT CCCACGTCGC GCATGCCGATG  
AACAGGGCGA TGGAAACATCT GTCAACATGAG GATGCACAAAA ATGTTGCTCC AGTGTATGAC  
CTGCTGCTGG AGATGCTGAA TGGCCAGCTG CTTCGGCGGGT GCAAGTCTCC CATCAGCGGG  
TCCGAGTGGC GCCCCGCGCA GGACAGTAAA AGCAAGAAGG GTTCGCCAGAA CCCACGCTCT  
CAGTGA  

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 530 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

```
Met  Asp  Ile  Lys  Asn  Ser  Pro  Ser  Ser  Leu  Asn  Ser  Pro  Ser  Ser  Tyr
   1      5  10      15
Asn  Cys  Ser  Glu  Ser  Ile  Leu  Pro  Leu  Glu  His  Gly  Ser  Ile  Tyr  Ile
   20     25  30
Pro  Ser  Ser  Tyr  Val  Asp  Ser  His  His  Glu  Tyr  Pro  Ala  Met  Thr  Phe
   35     40  45
Tyr  Ser  Pro  Ala  Val  Met  Asn  Tyr  Ser  Ile  Pro  Ser  Asn  Val  Thr  Asn
   50     55  60
```

SUBSTITUTE SHEET (RULE 26)
Leu Glu Gly Gly Pro Gly Arg Glu Thr Thr Ser Pro Asn Val Leu Trp
65
Pro Thr Pro Gly His Leu Ser Pro Leu Val Val His Arg Gln Leu Ser
85
His Leu Tyr Ala Glu Pro Gln Lys Ser Pro Trp Cys Glu Ala Arg Ser
100
Leu Glu His Thr Leu Pro Val Asn Arg Glu Thr Leu Lys Arg Lys Val
115
Ser Gly Asn Arg Cys Ala Ser Pro Val Thr Gly Pro Gly Ser Lys Arg
130
Asp Ala His Phe Cys Ala Val Cys Ser Asp Tyr Ala Ser Gly Tyr His
145
Tyr Gly Val Trp Ser Cys Glu Gly Cys Lys Ala Phe Phe Lys Arg Ser
165
Ile Gln Gly His Asn Asp Tyr Ile Cys Pro Ala Thr Asn Gln Cys Thr
180
Ile Asp Lys Asn Arg Arg Lys Ser Cys Gln Ala Cys Arg Leu Arg Lys
195
Cys Tyr Glu Val Gly Met Val Lys Cys Gly Ser Arg Arg Glu Arg Cys
210
Gly Tyr Arg Leu Val Arg Arg Gln Arg Ser Ala Asp Glu Gln Leu His
225
Cys Ala Gly Lys Ala Lys Arg Ser Gly Gly His Ala Pro Arg Val Arg
245
Glu Leu Leu Leu Asp Ala Leu Ser Pro Glu Gln Leu Val Leu Thr Leu
260
Leu Glu Ala Glu Pro His Val Leu Ile Ser Arg Pro Ser Ala Pro
275
Phe Thr Glu Ala Ser Met Met Ser Leu Thr Lys Leu Ala Asp Lys
290
Glu Leu Val His Met Ile Ser Trp Ala Lys Ile Pro Gly Phe Val
305
Glu Leu Ser Leu Phe Asp Gln Val Arg Leu Glu Ser Cys Trp Met
325
Glu Val Leu Met Met Gly Leu Met Trp Arg Ser Ile Asp His Pro Gly
340
Lys Leu Ile Phe Ala Pro Asp Leu Val Leu Asp Arg Glu Gly Lys
355
Cys Val Glu Gly Ile Leu Glu Ile Phe Asp Met Leu Leu Ala Thr Thr
370
4/7

Ser Arg Phe Arg Glu Leu Lys Leu Gln His Lys Glu Tyr Leu Cys Val 385 390 395 400
Lys Ala Met Ile Leu Leu Asn Ser Ser Met Tyr Pro Leu Val Thr Ala 405 410 415
Thr Gln Asp Ala Asp Ser Ser Arg Lys Leu Ala His Leu Leu Asn Ala 420 425 430
Val Thr Asp Ala Leu Val Trp Val Ile Ala Lys Ser Gly Ile Ser Ser 435 440 445
Gln Gln Ser Met Arg Leu Ala Asn Leu Leu Met Leu Ser His 450 455 460
Val Arg His Ala Ser Asn Lys Gly Met Glu His Leu Leu Asn Met Lys 465 470 475 480
Cys Lys Asn Val Val Pro Val Tyr Asp Leu Leu Glu Met Leu Asn 485 490 495
Ala His Val Leu Arg Gly Cys Lys Ser Ser Ile Thr Gly Ser Glu Cys 500 505 510
Ser Pro Ala Glu Asp Ser Lys Ser Lys Gly Ser Gln Asn Pro Gln 515 520 525
Ser Gln 530

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
Met Thr Phe Tyr Ser Pro Ala Val Met Asn Tyr Ser 1 5 10

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
Gly Tyr Ser Pro Ala Val Met Asn Tyr Ser 1 5 10

SUBSTITUTE SHEET (RULE 26)
(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
GGAAGCTGT CGACCATCAT GACCGCTAT AGCCCTGCTG TGATG

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
GGATCTAGAG TCGACCGGTC ACTGAGACTG AGGTTCTGG

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
Met Thr Gly Tyr

1

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

SUBSTITUTE SHEET (RULE 26)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

CCATCATGAC CGGCTAT

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

CTGGTGAACTT TAGCTTTTTT GTC

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GCTTGACACC AAGGACTCTT TTGAG

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GTGGGCAACA ACACATTG GCTTG

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

SUBSTITUTE SHEET (RULE 26)
(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

CCATCCTAAT ACGACTCACT ATAGGGC

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

ACTCACTATA GGGCTCGAGC GGC
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/12 C07K14/705 C07K16/28 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched.

Electronic data base consulted during the international search (name of data base and, where practical, search terms used).

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>P, X</td>
<td>EP 0 798 378 A (AKZO NOBEL NV) 1 October 1997 see the whole document</td>
<td>1-23</td>
</tr>
<tr>
<td>X</td>
<td>WO 97 09348 A (KAROBIO AB; KUIPER GEORGE G J M (SE); ENMARK EVA (SE); GUSTAFSSON) 13 March 1997 see the whole document</td>
<td>1-17, 19-23</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents:

*A* document defining the general state of the art which is not considered to be of particular relevance.

*E* earlier document but published on or after the international filing date.

*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another document(s) or for other special reasons (as specified).

*O* document referring to an oral disclosure, use, exhibition or other means.

*P* document published prior to the international filing date but later than the priority date claimed.

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone.

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"S" document member of the same patent family.

Date of the actual completion of the international search

30 September 1998

Date of mailing of the international search report

07/10/1998

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Nauche, S

Form PCT/ISA/210 (second sheet) (July 1992)
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP 0798378 A</td>
<td>01-10-1997</td>
<td>AU 1652197 A</td>
<td>02-10-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2200423 A</td>
<td>26-09-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 9700636 A</td>
<td>28-04-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 10004986 A</td>
<td>13-01-1998</td>
</tr>
<tr>
<td>WO 9709348 A</td>
<td>13-03-1997</td>
<td>AU 6988096 A</td>
<td>27-03-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2201098 A</td>
<td>13-03-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 792292 T</td>
<td>03-09-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0792292 A</td>
<td>03-09-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 98300029 T</td>
<td>30-04-1998</td>
</tr>
</tbody>
</table>